Trevi Therapeutics, Inc. Income Statement
TRVI / Health Care|7 years of annual SEC 10-K data (FY2018-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| SG&A Expense | $12.1M | $10.2M | $10.1M | $9.5M | $10.2M | $7.3M | $4.3M |
| R&D Expense | $39.4M | $23.7M | $19.8M | $23.0M | $22.3M | $19.3M | $14.1M |
| Operating Income | -$51.5M | -$33.9M | -$29.9M | -$32.5M | -$32.5M | -$26.6M | -$18.4M |
| Interest Expense | - | $391.0K | $1.2M | $1.2M | $456.0K | - | $174.0K |
| Income Tax | -$30.0K | -$32.0K | -$36.0K | -$21.0K | -$18.0K | -$18.0K | -$124.0K |
| Net Income | -$47.9M | -$29.1M | -$29.2M | -$33.9M | -$32.8M | -$26.1M | -$20.5M |
| EPS (Basic) | -$0.47 | -$0.29 | -$0.45 | -$1.49 | - | - | - |
| EPS (Diluted) | -$0.47 | -$0.29 | -$0.45 | -$1.49 | - | - | - |
| Shares Outstanding | 102.0M | 99.0M | 64.5M | 22.8M | 18.1M | 11.7M | 437.6K |